The Goldman Sachs Group, Inc. 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-13 5:52 pm Purchase | 2025-06-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | GOLDMAN SACHS GROUP INC GS | 5,581,828 6.500% | 1,071,159 (+23.75%) | Filing |
| 2025-05-09 12:34 pm Sale | 2025-03-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | GOLDMAN SACHS GROUP INC GS | 4,510,669 5.200% | -1,442,796 (-24.23%) | Filing |
| 2025-02-12 11:39 am Purchase | 2024-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | GOLDMAN SACHS GROUP INC GS | 5,953,465 7.000% | 5,953,465 (New Position) | Filing |